Segoviano-Mendoza G, Torres-Erazo DS, Tovar-Serrano A

Language: Spanish
References: 15
Page: 365-372
PDF size: 458.57 Kb.

ABSTRACT

Background: Hepatitis B and C virus (HBV/HCV) infection in HIVinfected individuals may escape at the immune control and generate chronic illness sometimes hidden.
Objective: To determine the existence of HIV co-infection with HBV or HCV, in patients treated at a private hospital in Mexico City.
Material and method: A cross-sectional study performed from October 2009 to June 2012 included all patients with HIV treated at infectology service of Sanatorium Durango Hospital Center, Mexico City. Were ordered: transaminases, serology for hepatitis A (HAV), HBV and HCV virus, viral loads of hepatitis B, C, HIV and CD4 count. The analysis was performed using SPSS 13.0.
Results: 41 patients were included, 90% (n = 37) were male and 82% (n = 34) were under HAART at the beginning of the evaluation; 32 attended the studies performed; 27 carried out HBV viral load, HCV and HIV, and 29 were submitted to viral hepatitis serology, finding that all had IgG against HAV. Nine patients showed antibodies against the surface antigen (31%) and one had anti-HCV antibodies (3.4%). Viral loads showed only one patient with detectable viremia of HBV and three with detectable viral load of HCV.
Conclusions: Patients living with HIV/AIDS, even though they are on antiretroviral treatment and adequate CD4 count and HIV viral load undetectable, may have active co-infection with HBV and even hidden and/or HCV, by emphasizing the importance of monitoring of that co-infection.

REFERENCES

1. Sackoff JE, Hanna DB, Pfeiffer MR, et al. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med 2006;145:397-406.

2. Lewden C, Salmon D, Morlat P, et al. Causes of death among human immunodeficiency virus HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 2005;43:121-130.

3. Krentz HB, Kliewer G, Gill MJ. Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 a 2003. HIV Med 2005;6:99-106.

4. Sulkowski MS, Mast EE, Seeff LB, et al. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infectious Dis 2000;30(Suppl.1):S77-84.

5. Soriano V, Martín-Carbonero L, Vispo E, et al. Infección por virus de la inmunodeficiencia humana y hepatitis víricas. Enfer Infecc Microbiol Clin 2011;29:691-701.

6. Panduro A, Escobedo-Melendez G, Fierro Nora, et al. Epidemiología de las hepatitis virales en México. Salud Pública Méx 2011;53:S37-S45.

7. Di Lello FA, Macías J, Cifuentes C, et al. Low prevalence of occult HBV infection among HIV-infected patients in southern Spain. Enferm Infecc Microbiol Clin 2012;30:312-314.

8. Centro Nacional para la Prevención y el control del VIH/ SIDA (CENSIDA). Guía de Manejo Antirretroviral de las personas con VIH. Quinta edición. México 2012. http:// www.censida.salud.gob.mx/descargas/atencion/GUIA_ ARV_2012.pdf

9. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral guidelines agents in HIV-1 infected adults and adolescents. Department of Health and Human Services. Disponible en: http://aidsinfo.nih.gov/contentfiles/adultandadolescentGL. pdf

10. European AIDS Clinical Society. Guidelines. Version 6.1-November 2012. Disponible en: http://www.eacsociety.org/ Guidelines.aspx

11. Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: A historical overview. Vaccine 2008;26:6266-6273.

12. Laguno M, Sánchez-Tapia JM, Murillas J, et al. Avances en el diagnóstico y tratamiento de la infección por el virus de la hepatitis C en pacientes con y sin infección por el VIH. Enferm Infecc Microbiol Clin 2005;23:32-40.

13. Rodriguez-Mendez ML, González-Quintela A, Aguilera A, et al. Association of HCV and HBV markers in Spanish HIV-seropositive patients in relation to risk practices. Hepatogastroenterol 2003;50:2093-2097.

14. Rockstroh J, Mocroft A, Soriano V, Tural C, et al. Influence of hepatitis C on HIV disease progression and response to antiretroviral therapy. J Infect Dis 2005;192:992-1002.

15. Soriano V, Mocroft A, Rockstroh J, Ledergerber B, et al. Spontaneous viral clearance, viral load, and genotype distribution of HCV in HIV-infected patients with HCV antibodies in Europe. J Infect Dis 2008;198:1337-1344.